Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Current Assets (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Current Assets data on record, last reported at $474.4 million in Q2 2025.

  • For Q2 2025, Current Assets changed N/A year-over-year to $474.4 million; the TTM value through Jun 2025 reached $474.4 million, changed N/A, while the annual FY2024 figure was $356.7 million, 39.27% up from the prior year.
  • Current Assets reached $474.4 million in Q2 2025 per TARS's latest filing, up from $356.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $474.4 million in Q2 2025 and bottomed at $176.0 million in Q4 2021.
  • Average Current Assets over 5 years is $248.2 million, with a median of $225.4 million recorded in 2022.
  • Peak YoY movement for Current Assets: dropped 26.69% in 2023, then soared 63.3% in 2024.
  • A 5-year view of Current Assets shows it stood at $176.0 million in 2021, then increased by 28.09% to $225.4 million in 2022, then rose by 13.65% to $256.1 million in 2023, then skyrocketed by 39.27% to $356.7 million in 2024, then skyrocketed by 33.0% to $474.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $474.4 million in Q2 2025, $356.7 million in Q4 2024, and $340.7 million in Q1 2024.